Loading...
•
Jun 30, 2021
Corvus Pharmaceuticals Q2 2021 Earnings Report
Corvus Pharmaceuticals reported financial results for the second quarter ended June 30, 2021.
Key Takeaways
Corvus Pharmaceuticals reported a net loss of $11.8 million for the second quarter ended June 30, 2021. As of June 30, 2021, Corvus had cash, cash equivalents and marketable securities totaling $66.5 million.
Advanced mupadolimab, focusing on HPV positive head and neck cancer and other viral associated cancers.
Mupadolimab is believed to improve patient outcomes due to its dual mechanism of inhibiting immunosuppressive adenosine and enhancing antibody responses to viruses.
Angel Pharmaceuticals filed an IND in China to initiate Phase 1/2 clinical development of CPI-818 for the treatment of T cell lymphomas.
With the discontinuation of the mupadolimab Phase 3 clinical trial in COVID-19, Corvus now expects full year 2021 net cash used in operating activities to be between $35 million and $37 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...